Polymeric Core‐shell Nanoparticles for Therapeutics

Yang, Yi Yan; Wang, Yong; Powell, R. S.; Chan, Peggy

doi:10.1111/j.1440-1681.2006.04408.x

Cited by 77 publications

(56 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For gene delivery, both organic and inorganic polymeric nanoparticles have been extensively explored, and cationic polymeric nanoparticles exhibit strong gene binding and high transfection potential with low toxicity (47); however, for cancer gene therapy, the efficiency of transfection has to be improved considerably. Polymeric nanoparticles also hold promise for peptide and protein delivery and have been successfully used for delivery of small peptides (i.e., insulin and calcitonin) in animal models (47). Polymeric nanoparticles could be specifically designed for in vivo delivery of maspin (or its active fragments).…”

Section: Potential Therapeutic Use Of Maspinmentioning

confidence: 99%

Maspin: The New Frontier

Khalkhali‐Ellis

2006

Clinical Cancer Research

114

117

View full text Add to dashboard Cite

Maspin (mammary serine protease inhibitor) was identified in 1994 by subtractive hybridization analysis of normal mammary tissue and breast cancer cell lines. Subsequently, emerging evidence portrays maspin as a multifaceted protein, interacting with diverse group of intercellular and extracellular proteins, regulating cell adhesion, motility, apoptosis, and angiogenesis and critically involved in mammary gland development. The tissue-specific expression of maspin is epigenetically controlled, and aberrant methylation of maspin promoter is closely associated with maspin gene silencing. Identification of new tissue sites expressing maspin and novel maspin-binding partners has expanded the horizon for maspin research and promises maspin-based therapeutic approaches for combating cancer. This perspective briefly outlines the past and present strides in deciphering this unique molecule and speculates on new frontiers in maspin research and prospects of maspin as a diagnostic/prognostic indicator in cancer.The serine protease inhibitor superfamily (serpins) is categorized to inhibitory and noninhibitory serpins (1). Inhibitory serpins use their reactive center loop to trap the target proteinase and inhibit its activity (1). The noninhibitory serpins have shorter NH 2 and COOH termini, and they also lack the classic serpin secretory signal peptide (1). Recent studies indicate serpins function beyond their serpin properties: they are involved in cell adhesion and play a role in extracellular matrix remodeling (2).Maspin (mammary serine protease inhibitor) shares sequence homology with inhibitory serpins, such as plasminogen activator inhibitors 1 and 2, a-1 anti-trypsin, and noninhibitory serpin ovalbumin (3), and several recent sequence comparisons seem to suggest that maspin is more closely related to noninhibitory clade B serpins. The reactive center loop of maspin is significantly shorter than that of most inhibitory serpins, and maspin does not undergo conformational rearrangement required to inactivate target protease(s) (4). However, the reactive center loop of maspin is clearly important for its function; studies using synthetic maspin reactive center loop peptides and maspin/ovalbumin chimeras reveal that this region is important for promoting cell adhesion (5).In the past decade, with the expansion of studies on maspin, novel protein-binding partners have been identified and provided insight into the molecular aspects of its regulation and its divergent mechanism of action. More importantly, they have presented new prospects for therapeutic interventions for breast, prostate, and many other cancers.

show abstract

Section: Potential Therapeutic Use Of Maspinmentioning

confidence: 99%

Maspin: The New Frontier

Khalkhali‐Ellis

2006

Clinical Cancer Research

114

117

View full text Add to dashboard Cite

show abstract

“…Novel methods such as nanodelivery systems would also improve biodistribution of cancer drugs and the pharmacokinetic profile [25]. Paclitaxel is one such anti-neoplastic drug that is used in cancer therapy known for its aqueous insolubility [16,16], which, as a result, is associated with increased binding to blood protein limiting its ability in treatment of solid tumors [10,26]. Currently, paclitaxel is administered in two forms, one as Taxol that is formulated by dissolving the mixture of dehydrated ethanol and Cremophor EL and Abraxane, which is an albumin, based nanoparticle formulation [23,44].…”

Section: Discussionmentioning

confidence: 99%

“…These include drug delivery systems that are submicron sized particles (92 -200 nm), that can be made using a variety of materials and configurations such as but not limited to micelles, dendrimers, nanoemulsions, liposomes, viruses and organometallic compounds [9,10,24,26,27].…”

Section: Articlementioning

confidence: 99%

“…These high mortality rates and adverse side effects are usually the result of (a) most of the anti-cancer drugs (> 70%) being lipid soluble and (b) therapeutic doses are often very high. Nanoemulsion-based drug delivery systems can be used to enhance the chemotherapeutic properties of a drug by reducing the particle size of the typical anti-cancer drug formulation up to 100 fold (microns to 20 nm) thereby increasing the drug's bioavailability (absorption into the blood stream) and efficacy (inhibition of uncontrolled cell proliferation) [8][9][10][11]. One such drug used in breast cancer chemotherapy is paclitaxel (Taxol ® ) which has very strong antitumor activity, but has low aqueous solubility thus requiring a high therapeutic dose for effectiveness [12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vitro Evaluation of Antiproliferative Effects of Self-assembling Nanoemulsion of Paclitaxel on Various Cancer Cell Lines

Bagul¹,

Kakumanu²,

Wilson³

et al. 2010

Nano BioMed ENG

View full text Add to dashboard Cite

Paclitaxel is routinely used in cancer chemotherapy to treat patients with ovarian, breast, lung, head and neck cancers. However, because of its low aqueous solubility, it's been administered as a Cremophor EL and ethanol solution, which is associated with increased toxicity and high therapeutic dose requirements. The goal of the present study was to formulate paclitaxel into a self assembling nanoemulsion (SANE) and demonstrate the effects of paclitaxel SANE formulation on the inhibition of cell proliferation in breast (80 %), colon (60 %), and pancreatic cell lines (60 %) compared to blank nanoemulsion. In addition, nanoemulsions of paclitaxel with a mean particle size of 20 nm dramatically reduced zeta potential and showed up to 12 fold greater apoptosis in the PL-45 pancreatic cancer cell line compared to a blank nanoemulsion. In conclusion we have developed a SANE formulation of paclitaxel having a particle size of 20 nm which significantly inhibited cell proliferation, dramatically reduced zeta potential and increased apoptosis by 12-fold when compared to a blank and nanoemulsion, thus indicating the therapeutic potential for SANE as an anti-cancer drug delivery system.

show abstract

“…These polymers can be formulated into novel nanocarriers encapsulating hydrophilic or hydrophobic anticancer drugs [4,8,[215][216][217]. Natural and synthetic polymers have already been used for drug delivery in preclinical and clinical studies [218].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Supramolecular nanoscale assemblies for cancer diagnosis and therapy

Coelho

Pereira

Juzeniene

et al. 2015

Journal of Controlled Release

View full text Add to dashboard Cite

Nanocarriers based on polymers, metals and lipids have been extensively developed for cancer therapy and diagnosis due to their ability to enhance drug accumulation in cancer cells and decrease undesired drug toxicity in healthy tissues. Overcoming multidrug resistance by designing proper drug nanocarriers will improve outcome of existing oncologic treatments such as chemotherapy or radiotherapy. In this article the relation between physicochemical properties and capacity of a nanosystem to deliver therapeutic agents into pathological sites is discussed. Most promising examples of drug delivery systems are reviewed, and, in particular, the design of a carbohydrate based matrix with entrapped gold nanoparticles is highlighted.

show abstract

Polymeric Core‐shell Nanoparticles for Therapeutics

Cited by 77 publications

References 82 publications

Maspin: The New Frontier

Maspin: The New Frontier

In vitro Evaluation of Antiproliferative Effects of Self-assembling Nanoemulsion of Paclitaxel on Various Cancer Cell Lines

Supramolecular nanoscale assemblies for cancer diagnosis and therapy

Contact Info

Product

Resources

About